RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, vol.15, no.2, pp.154-164, 2020 (SCI-Expanded)
Background: Cancer is characterized by overexpression of p53 associated proteins, which down-regulate P53 signaling pathway. In cancer therapy, p53 activity can be restored by inhibiting the interaction of MDMX (2N0W) and MDM2 (4JGR) proteins with P53 protein.